Mark Shackleton
Overview
Explore the profile of Mark Shackleton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
7233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ugalde A, Tothill R, Quinn S, Wong H, Prall O, Mitchell C, et al.
BMC Cancer
. 2025 Jan;
25(1):171.
PMID: 39881222
Background: People with malignancy of undefined primary origin (MUO) have a poor prognosis and may undergo a protracted diagnostic workup causing patient distress and high cancer related costs. Not having...
2.
Wu L, Park S, Jakobsson H, Shackleton M, Moller A
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893071
Melanoma is commonly diagnosed in a younger population than most other solid malignancies and, in Australia and most of the world, is the leading cause of skin-cancer-related death. Melanoma is...
3.
Andrews M, Li G, Graf R, Fisher V, Mitchell J, Aboosaiedi A, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2300640.
PMID: 38848517
Purpose: The choice of threshold and reliability of high tumor mutational burden (TMB) to predict outcomes and guide treatment choice for patients with metastatic melanoma receiving first-line immune checkpoint inhibitor...
4.
ODay R, Conway R, Lim L, Giblin M, Cherepanoff S, Joshua A, et al.
Can J Ophthalmol
. 2024 May;
59(5):e525-e533.
PMID: 38810958
Objective: To describe the development of a web-based data collection tool to track the management and outcomes of uveal melanoma patients. Design: Description of a clinical registry. Participants: Patients with...
5.
Walpole I, Zaman F, Zhao P, Marshall V, Lin F, Thomas D, et al.
Clin Transl Med
. 2024 Apr;
14(4):e1657.
PMID: 38629623
Purpose: Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for...
6.
Knox A, Wang T, Shackleton M, Ameratunga M
Exp Dermatol
. 2024 Apr;
33(4):e15075.
PMID: 38610093
Although clinical outcomes in metastatic melanoma have improved in recent years, the morbidity and mortality of symptomatic brain metastases remain challenging. Response rates and survival outcomes of patients with symptomatic...
7.
Hiong A, ODay R, Fog L, McKay D, McKenzie J, Ameratunga M, et al.
Ophthalmol Retina
. 2023 Oct;
8(4):325-330.
PMID: 37852320
Purpose: To report the effective use of neoadjuvant darovasertib and crizotinib in a patient with a large uveal melanoma (UM) in his only functional eye. Design: Case report. Subjects: One...
8.
Edwards J, Andrews M, Burridge H, Smith R, Owens C, Edinger M, et al.
Clin Transl Immunology
. 2023 Sep;
12(9):e1466.
PMID: 37692904
Objectives: Despite the success of immune checkpoint blockade, most metastatic melanoma patients fail to respond to therapy or experience severe toxicity. Assessment of biomarkers and immunophenotypes before or early into...
9.
Yeoh H, Freilich K, Voskoboynik M, Moore M, Andrews M, Shackleton M, et al.
Aust J Gen Pract
. 2023 Jun;
52(6):378-385.
PMID: 37291817
Background: Immunotherapy has reshaped the prognoses for many cancers and is increasingly used in both metastatic and adjuvant settings. There is a high prevalence of immunotherapy side effects, or immune-related...
10.
Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele C, et al.
Oncogene
. 2023 Mar;
42(17):1360-1373.
PMID: 36906655
Cellular heterogeneity in cancer is linked to disease progression and therapy response, although mechanisms regulating distinct cellular states within tumors are not well understood. We identified melanin pigment content as...